Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, accessing the U.S. biotech's experimental drug to treat ...

GSK has agreed to buy a pharmaceutical firm that is developing treatment for people with food allergies in a deal valued at 2 ...

FM6SS and GSK Maroc signed a strategic partnership for biomedical research, therapeutic innovation, and medical practices across Morocco.

Britain's GSK will buy RAPT Therapeutics for $2.2 billion, adding global rights to the U.S. firm's experimental food allergy ...

Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV specialist ViiV Healthcare in a deal that ...

Under the terms of the agreement, GSK will pay RAPT Therapeutics shareholders $58.00 per share at closing for an estimated ...

As a result of the acquisition, Pfizer will no longer hold shares of ViiV Healthcare Limited and Shionogi will see its holdings increase to 21.7%. 1 The majority shareholder of ViiV Healthcare Limited ...

Propeller Health, a company that trains its digital eye on respiratory medicine, first partnered with GSK in 2015. Now, that collaboration is being expanded -- enabling both companies to prepare for, ...

GSK plc (NYSE:GSK) is one of the best performing pharma stocks in 2025. Jefferies reaffirmed a Buy rating on GSK plc ...

We recently compiled a list of the 10 Best Healthcare Stocks to Buy Under $50. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other healthcare stocks under ...

GlaxoSmithKline will purchase Novartis’ 36.5 percent stake in their consumer healthcare joint venture for $13 billion, according to Reuters. Here are four things to know. 1. The $13 billion ...

ViiV Healthcare announced Wednesday the latest findings from its EMBRACE phase 2b study. The study found that N6LS (VH3810109 or VH109), given every four months in combination with monthly ...